CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the transcatheter treatment of atrial fibrillation (AF), announced its technology enables a pulmonary vein (PV) acute isolation rate of nearly 99%, with...
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the transcatheter treatment of atrial fibrillation (AF), announced its technology enables a pulmonary vein (PV) acute isolation rate of nearly 99%, with...
CardioFocus, Inc., developer of...